An editorial publisher, not a clinic.

What this datasheet is

Doctor CJC-1295 reads the peer-reviewed literature on CJC-1295 — a long-acting GHRH analog also logged as CJC-1295 with DAC, DAC:GRF, and the closely related non-DAC backbone modified GRF(1-29) — and lays it out like a datasheet. The work is reading, summarizing, citing, and structurally organizing publicly available scientific publications, ClinicalTrials.gov records, FDA actions, and World Anti-Doping Agency documents; nothing is set down that a source does not support.

No examining room stands behind the datasheet. There is no clinician on staff, nothing to prescribe, and nothing to buy — the site reads and cites the record, and that is the whole of it.

On the name

The 'doctor' prefix in the domain is a stance toward the literature, not a description of services — a position the publisher takes relative to the record. In this datasheet it reads as 'chief engineer' rather than 'physician,' matching the engineering-spec frame of the design. Nothing here is a consultation, a prescription, an examination, or a diagnosis. There is no clinical staff, no address to visit, no practice, and no clinical relationship of any kind between this page and any reader.

The distinction matters because the published CJC-1295 record sits squarely on the research-chemical side of the line. The compound is not approved for any human therapeutic indication, and no legitimate clinician prescribes it as an approved drug. A site dressing itself up as a clinic for CJC-1295 would misstate both the compound and the regulatory architecture. This is a publisher's read of what the record says — nothing more.

Editorial standards

Every quantitative claim here is pinned to a primary source — peer-reviewed publication, registered trial, FDA action, or WADA document. The full citation list lives on the References page with DOIs and stable identifiers. Outbound links are to primary sources only: PubMed, PMC, NIH, ClinicalTrials.gov, the FDA website, the WADA website, and the journals themselves.

When a claim sits in the research literature with limits — small sample size, single-cohort design, terminated trial, in vitro only, class-comparator extrapolation — those limits are stated. The CJC-1295 evidence base is unusually shallow for a peptide with this much downstream usage; the editorial framing is to make the shallowness visible rather than to paper over it.

No prescriptive language appears anywhere on the site. We describe what was studied or what regulators have said; we do not recommend doses or routes or protocols. Where a number appears, it is sourced and attributed.

What this datasheet is not

This is not a medical practice, a telehealth service, a compounding pharmacy, or a research-chemical vendor, and it holds no tie to any vendor, manufacturer, pharmacy, telehealth provider, clinic, or commercial source of CJC-1295 or a related peptide. It links to no vendor pages and promotes no commercial source. The CJC-1295 evidence base is a research-chemical record, and what you are reading is a datasheet drawn from it.